Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: * TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K(V)7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K(V)7 and Na(V)1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.